Exclusive: Granules India CFO Sandip Neogi tells Anil Singhvi - expect CAGR of 30 pct

In today’s edition of 'News Par Views' show, Zee Business Managing Editor Anil Singhvi spoke to Sandip Neogi, Chief Financial Officer (CFO) of Granules India, a leader in API (Active Pharmaceutical Ingredient) manufacturing in the country. Neogi spoke about the recent buzz regarding the stake sale in company and much more. (#NewsParViews)

Neogi revealed that with Granules India doing well, proposals for acquiring stakes in the company had come. However, he refused to comment any further. The CFO said that the Granules India management's complete focus is on driving the performance of the company. 

Watch Zee Business Tweet Video Below:

The maker of Paracetamol tablets, Granules India is a very stable supplier in the global markets. He called these molecules “evergreen”. He added that Granules India has no direct correlation with the Covid-19 vaccine. He was responding to a question if the company had any business interests related to Covid-19 vaccine, as the entire world was now anticipating a Covid 19 vaccine in the markets anytime soon.  

He conceded that there was some slight impact on Granules India's export of tablets during February and March months, when the news around Covid-19 began pouring in.  

Granules India, which began operations in 1984, had come out with its first public issue in 1995. The company has presence in 75 countries and around 60 per cent of the business come from Europe and the US. 

Road Ahead 

Granules India expects a growth of 60-70 per cent in its bottomline for this financial year as against the previous year, Neogi said based on the guidance it has given on performance and the business plan. 

See Zee Business Live TV Streaming Below:

If FY21 is taken as the baseline, then Granules India expects to grow at a CAGR of 30 per cent, he added.